Development of a VesiVax® HIV Vaccine Formulation

Awarded Award Notice Posted

Solicitation number
PHS2021-1
Agency
National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
Awarded
to Molecular Express, Inc.
Set-aside
Total Small Business

Opportunity facts

Contract number
75N93021C00027 Federal contract award
NAICS code
54171 Research and Development in the Physical, Engineering, and Life Sciences
PSC
AN11 Health R&D Services; Health Care Services; Basic Research
Place of performance
Rancho Dominguez, California 90220, United States

Notice details come from SAM.gov. Updated .

About this opportunity

Molecular Express Inc. was awarded a $2,294,565 contract by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to develop a VesiVax HIV vaccine formulation intended to help prevent the transmission and progression of HIV/AIDS through 2023. This total small business set aside contract supports the contractor's work advancing the development of a vaccine to address this important public health issue by developing a VesiVax HIV vaccine formulation by 2023.

Notice text

Awarded contract 75N93021C00027 to Molecular Express Inc for 2294565.00 on 2021-07-01.

Notice history

On GovTribe

Work this opportunity on GovTribe

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity